Vivacelle Bioincis A Developmental Stage Biotechnology Companydeveloping Products Utilizing Nanoparticle Technology Their First Productvbi 1A Colloid Non Blood Volume Expander Appears To Be Safer And Far More Effective Than The Standard Treatment For Hypovolemia In Animal Studies And Received Green Light From Fda To Start A Phase Iia Clinical Trial In Hypovolemia Due To Blood Lossthe Immediate Other Product In The Pipeline Is Vbi Stargeting Hypovolemia Due To Sepsis Septic Shock Hypovolemia Results From Inadequate Fluid Volume In The Blood Vesselscauses The Death Of Over A One Million People Globally Each Year Major Causes For Fluid Loss Are Traumasurgeryshocksepsissevere Diarrhea And Burns Inadequate Circulating Volume Impairs Tissue Perfusion And Oxygenation Leading To Cell Injury And Deathrapid Volume Replacement And Re Establishment Of Normal Blood Pressure Are Essential For Survivalcurrentlyavailable Options Of Fluid Replacements Are Non Blood Volume Expanderscolloids And Crystalloids Blood Products And Blood Substitutesthey Have Proven To Be Impractical And Have The Potential For Significant Negative Adverse Effectsvbi 1 Represents A New Paradigm In Fluid Resuscitationsafely Restoring Blood Vessel Volume And Reversing The Effects Of Hypovolemia Vbi 1 Also Modulates Nitric Oxidea Potent Vasodilator That Drops The Blood Pressure And A Precursor To Highly Highly Toxic Mediators Reduces Reperfusion Injuryinhibits The Inflammatory Responseclears The Endotoxinmetabolizes To Naturally Occurring Components And Acts As An Energy Sourcein Additionit Can Be Loaded With Readily Available Oxygen
No conferences found for this company.
| Company Name | Vivacelle Bio Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
